SURPRISE Study Group
Quick facts
Marketed products
- Tocilizumab plus methotrexate · Immunology
Tocilizumab blocks IL-6 receptor signaling to reduce inflammation, while methotrexate inhibits dihydrofolate reductase to suppress immune cell proliferation.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: